Progress towards gene therapy for cancer

Journal of Experimental and Clinical Cancer Research

Volumn 19, Issue 3, 2000, Pages 261-270

  Marchisone, C ^a   Pfeffer, U ^a   Del Grosso, F ^a   Noonan, D M ^a   Santi, L ^a   Albini, A ^a  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Cancer; Clinical Trials; Gene Therapy; Immunotherapy; Vectors

Indexed keywords

VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESEARCH; GENE THERAPY; GENE TRANSFER; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; NEOPLASMS; RETROVIRIDAE;

EID: 0033759086     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Gene therapy
2. Cancer gene therapy: Principles, problems and perspectives
3. Gene transfer m tumor therapy
4. Biology of desease: The biology of cancer gene therapy
5. Cytokine-based gene therapy of human tumors. An overview
6. Gene therapy for cancer: What have we done and where are we going?
7. Antiangiogenic gene therapy
8. Therapeutic potentials of angiostatin in the treatment of cancer
9. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach
10. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta
11. Targeted vectors for gene therapy
12. Transfer of genes to human: Early lesson and obstacles to success
13. Cytokine gene transduction in the immunotherapy of cancer
14. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor
15. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using TIL modified by retroviral gene transduction
16. The development of new cancer therapies based on the molecular identification of cancer regression antigens
17. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes
18. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity
19. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer
20. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B 7, in patients with metastatic melanoma
21. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity
22. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7- 2 costimulatory molecules
23. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
24. Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study
25. Gene therapy of glioblastoma - One year clinical experience with ten patients
26. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
27. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
28. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation
29. Tumor suppressor genes
30. Tumor suppressor gene workshop
31. Rb-1 oncosuppressor gene over-expression inhibits turnout progression and induces melanogenesis in metastatic melanoma cells
32. p53 mutation in human cancers
33. p53 tumor suppressor gene therapy for cancer
34. The role of the p 53 tumour suppressor gene in human breast cancer
35. Wild-type but not mutant p 53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions
36. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways
37. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effects of Ad5CMV-p 53
38. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p 53 gene via a recombinant adenovirus
39. Retrovirus-mediated wild-type p 53 gene transfer to tumors of patients with lung cancer
40. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p 53
41. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications
42. Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein
43. Intracellular antibodies (intabodies) as research reagents and therapeutic molecules for gene therapy
44. Gene marking to determine wherther autologous marrow infusion restores long-term haematopoiesis in cancer patients
45. Genetic marking shows that Ph+ cells present in autologous trasplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
46. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
47. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
48. Preotection of mice from lethal doses of methotrexate by trasplantation with transgenic marrow expressing drug resistant dihyrofolate-reductase activity
49. A gene transfer for marking bone marrow cells resistant to trimexate
50. Gene therapy in the C.N.S.
51. Activation of neurotrophin- 3 receptor TrkC induces apoptosis in medulloblastomas
52. Gene therapy of experimental brain tumors using neural progenitor cells
53. Retrovirus-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice
54. In vitro and in vivo targeting of gene expression to melanoma cells
55. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences
56. Construction and use of a safe and efficient amphotropic packaging cell line
57. Construction of retroviral vectors with improved safety, gene expression, and versatily
58. Protection of retroviral vector particles in human blood through complement inhibition
59. Stimulation of the adenovirus major late promoter in vitro by transcription factor USF is enhanced by the adenovirus DNA binding protein
60. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
61. Cytotoxic T-lymphocyte target proteins and their histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
62. Researchers and regulators reflect on first gene therapy death
63. US gene therapy in crisis
64. Stable in vivo expression of the cystic fibrosis transmembrane conductane regulator with an adeno-associated virus vector
65. Adeno-associated virus vectors transduce primary cells much less afficiently than immortalized cells
66. Adeno-associated virus vector integration junctions
67. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
68. Highly efficient and sustained gene transfer m adult neurons with a lentivirus vector
69. Stable and efficient gene transfer into the retina using an HIV-basedlentiviral vector
70. Sustained expression of genes delivered into liver and muscle by lentiviral vectors
71. Herpes simplex virus vectors for gene therapy
72. Potential and limitations of a gamma 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS
73. A gamma 34.5 mutant of herpes simplex 1 causes severe inflammation in the brain
74. Inflammatory effects of gene transfer into the CNS with defective HSV- 1 vectors
75. Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs
76. Enhanced gene delivery system and mechanism studies with a novel series of cationic lipid formulation